Prior to UroGen, Ms. Barrett was CEO of Novartis Oncology and a member of the Executive Committee of Novartis. She previously served as Global President of Oncology at Pfizer Inc. At Pfizer, she held numerous leadership positions, including President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and President of United States Oncology. Prior to Pfizer, she was Vice President and General Manager of the Oncology Business Unit at Cephalon Inc. Ms. Barrett also worked at Johnson & Johnson. She started her career at Kraft Foods Group Inc. Ms. Barrett holds a Bachelor of Science from the University of Louisiana and a Master of Business Administration from Saint Joseph’s University.
Peter P. Pfreundschuh
Chief Financial Officer
Mr. Pfreundschuh is a seasoned Executive with extensive industry experience. He previously served as the CFO of Sucampo Pharmaceuticals, Inc. where he played a critical role in its recent acquisition by Mallinckrodt for $1.2 Billion in February 2018. Prior to joining Sucampo, Mr. Pfreundschuh was Executive Vice President of Finance and CFO of Immunomedics Inc., a late-stage biopharmaceutical company focused on development of therapeutic agents in areas of oncology and immunology. Before this, he was CFO for CircuLite, Inc., a global medical device company that was sold in 2013. Mr. Pfreundschuh’s previous roles include leadership positions in finance, commercial operations and business development within the pharmaceutical industry at AstraZeneca Pharmaceuticals LP, and Johnson & Johnson. He is currently a board member of Speratus Therapeutics, Inc., and GitBasic LLC. Mr. Pfreundschuh has also previously served as an advisor or board member to Immunomedics Inc., CircuLite Inc., and Reproductive Medical Associates of New Jersey, in addition to other companies and private organizations. He holds a B.S. degree in accounting from Rutgers University School of Business, an M.B.A in Finance from Rider University Graduate School of Business, and completed Masters coursework in Strategic Marketing for the Healthcare Industry at Northwestern University’s Kellogg School of Management. Mr. Pfreundschuh is a Certified Public Accountant (CPA) licensed in the State of New Jersey, and started his career with Ernst & Young LLP.
Mark P. Schoenberg, M.D.
Chief Medical Officer
Mark Schoenberg, MD is an internationally recognized expert in the treatment of urothelial cancer. He received his undergraduate degree from Yale University, his MD from The University of Texas (Houston) and served as a resident in surgery and urology at The Hospital of The University of Pennsylvania. Under the auspices of The American Cancer Society, Dr. Schoenberg completed his fellowship in Urologic Oncology in The James Buchanan Brady Urological Institute of The Johns Hopkins University. Dr. Schoenberg is an active investigator and contributor to the peer-reviewed literature on urologic oncology. He has held prominent roles at several major US universities and served as the Bernard Schwartz Distinguished Professor of Urologic Oncology at Johns Hopkins University from 2005-2014. Dr. Schoenberg is a founding member of the scientific advisory board of The Bladder Cancer Advocacy Network.
Chief Operating Officer
Mr. Mullennix is a seasoned executive with deep experience in growth enterprises’ operations and finance, private equity and corporate finance, and the deployment of breakthrough technologies in highly regulated industries. Mr. Mullennix previously served as Chief Financial Officer and Senior Vice President of Operations for SolarReserve, LLC, a global power company that commercialized a breakthrough technology allowing for utility-scale generation and storage of solar power. Prior to SolarReserve, Mr. Mullennix served as a Managing Director at US Renewables Group, a private equity investment fund with more than $750 million of assets under management, Associate Vice President at AECOM Technology Company, and a Co-Founder of Ennix Incorporated, a family wastewater business which serves small municipalities. Mr. Mullennix has been a leader of teams that have won significant awards, including Commercial Application of the Year from Platts Global Energy Awards 2016, Rising Star Company from Platts Global Energy Awards 2015, Acquisition International Business Excellence 2015 Award, and Deloitte Technology Fast 500 2014 #1 Fastest Growing Cleantech Company.
Senior Vice President, Commercial
Jeffrey Bova has served as our Senior Vice President of Commercial since October 2017. Mr. Bova is a pharmaceutical commercial leader with extensive leadership experience across key commercial functional areas, including national sales, marketing and managed care. Mr. Bova joined UroGen Pharma after 20 years at Bayer Healthcare, where he held multiple senior-level sales leadership positions of increasing responsibility. Most recently at Bayer, Mr. Bova served as Vice President of Oncology Sales where he led over 200 field-facing sales representatives marketing well-known brands including Xofigo®, Stivarga® and Nexavar®. Mr. Bova also previously served as Bayer’s Vice President of Marketing for Bayer’s prostate cancer franchise where he designed, developed and led Bayer’s highly successful launch of Xofigo®. Mr. Bova received his M.B.A. from Xavier University and his B.S. in finance and marketing from the University of Cincinnati.
Woody Bryan, Ph.D.
Senior Vice President, Business Development
Dr. Bryan has served as our SVP of Business Development since September 2018. He was previously SVP of Business Development at Sucampo Pharmaceuticals, Inc., where he spearheaded the business development effort for its recent acquisition by Mallinckrodt Pharmaceuticals for $1.2 billion earlier this year. In this role, he also led the evaluation of several in-licensing opportunities and acquisition of multiple assets. Prior to joining Sucampo, Dr. Bryan was SVP of Business Development at Lupin Pharmaceuticals, Inc. His previous roles include VP of Business Development, Licensing at Supernus Pharmaceuticals, Inc. and VP of Business Development, Licensing and Project Management at Shire Laboratories, Inc. (a Division of Shire Pharmaceuticals Group). He is currently a Board Member of Afecta Pharma and a Board Member and past Chairman of Clemson University’s Spiro Institute of Entrepreneurial Leadership and Innovation. Dr. Bryan holds a B.S. in zoology from Clemson University, a Ph.D. in pharmaceutical sciences from the Medical University of South Carolina, and an Executive Management Certificate from the University of North Carolina at Chapel Hill Kenan-Flagler School of Business.
Marina Konorty, Ph.D.
Senior Vice President, R&D and Head of Israel Operations
Dr. Konorty joined UroGen as Chief Chemist in 2011. In this role, she was responsible for development of RTGel formulation including control of the RTGel’s delivery properties, their suitability as a drug carrier in humans, development of the drug products manufacturing processes and specifications, and optimization of UroGen’s pipeline based on RTGel platform technology. Prior to UroGen, Dr. Konorty served as Project Manager at TransPharma Medical, a medical device and drug delivery company. A published author with multiple patents, Dr. Konorty holds a BSc and MSc in Chemical Engineering from the Technion Institute of Technology and a PhD in Organic Chemistry from the Weizmann Institute of Science.
James Ottinger, R.Ph.
Senior Vice President, Regulatory Affairs
James Ottinger has served as our Senior Vice President of Regulatory Affairs since October 2017. Mr. Ottinger is a seasoned regulatory executive with over 30 years of strategic regulatory leadership experience and has successfully supported the development, approval, and marketing of multiple new drugs throughout his career. Prior to joining UroGen Pharma, Mr. Ottinger served as Senior Vice President of Global Regulatory Affairs at Teva Pharmaceutical Industries, Inc., where he was responsible for global regulatory oversight of Teva’s portfolio of branded, generic, and over-the-counter products. Previously, Mr. Ottinger was Vice President of Worldwide Regulatory Affairs of Cephalon, Inc. (acquired by Teva). Earlier in his career, Mr. Ottinger held a variety of senior regulatory leadership positions with Premier Research Group Limited, and regulatory positions of increasing responsibility at Wyeth Research (acquired by Pfizer, Inc.). Mr. Ottinger received his B.S. in Pharmacy from the Temple University School of Pharmacy and is a registered pharmacist in the State of Pennsylvania.
Elyse Seltzer, M.D.
Senior Vice President, Clinical Development
Elyse Seltzer, MD, has served as our Senior Vice President of Clinical Development since December 2017. Prior to joining UroGen, Dr. Seltzer served as Chief Medical Officer of Nabriva Therapeutics, where she was a key member of the management team that took the company public and was responsible for clinical and regulatory strategy and implementation of the Company’s clinical development programs. Dr. Seltzer joined Nabriva from GlaxoSmithKline (GSK), where she was Vice President of Global Clinical Sciences and Operations. Prior to joining GSK, Dr. Seltzer served as Chief Medical Officer at Tengion, a regenerative medicine company, where she established and built the Company’s clinical organization. Dr. Seltzer previously held senior clinical development roles at Centocor and Vicuron, and began her industry career at SmithKline Beecham (now GSK). Before joining the pharmaceutical industry, she was a practicing physician in Infectious Diseases. Dr. Seltzer holds an M.D. from the New York University School of Medicine, completed her Internal Medicine training at the University of Pennsylvania Medical Center and her Infectious Diseases training at Yale New Haven Hospital.
499 Park Avenue, Suite 1200
NY 10022, U.S.A
+1-646-768-9780 ext 1001